Lomtegovimab Biosimilar - Anti-Spike RBD mAb - Research Grade
Source
CAS: 2550869-33-3
Species
Homo sapiens
Expression system
XtenCHO
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Lomtegovimab,BI 767551, BI-767551, DZIF-10c, EX 14870, EX-14870,Spike RBD,anti-Spike RBD
Reference
PX-TA1801
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Lomtegovimab Biosimilar - Anti-Spike RBD mAb - Research Grade
Lomtegovimab Biosimilar: A Promising Antibody for Targeting the Spike Protein of SARS-CoV-2
Introduction
Lomtegovimab Biosimilar, also known as Anti-Spike RBD mAb, is a monoclonal antibody developed as a biosimilar to the therapeutic antibody lomtegravir. It is designed to specifically target the receptor binding domain (RBD) of the spike protein of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. In this article, we will discuss the structure, activity, and potential applications of this promising antibody.
Structure of Lomtegovimab Biosimilar
Lomtegovimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable domain and a constant domain. The variable domain of the antibody is responsible for binding to the RBD of the spike protein, while the constant domain mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Activity of Lomtegovimab Biosimilar
Lomtegovimab Biosimilar has been shown to bind with high affinity to the RBD of the spike protein, preventing its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. This binding not only inhibits viral entry into cells but also blocks the fusion of the viral membrane with the host cell membrane, preventing viral replication. Additionally, the antibody has been shown to induce ADCC and CDC, leading to the destruction of virus-infected cells.
Therapeutic Target: Spike Protein of SARS-CoV-2
The spike protein of SARS-CoV-2 is a trimeric glycoprotein that plays a crucial role in viral entry and infection. It consists of two subunits, S1 and S2, with the RBD located on the S1 subunit. The RBD binds to the ACE2 receptor on human cells, facilitating viral entry and replication. Therefore, targeting the RBD with an antibody such as Lomtegovimab Biosimilar can effectively prevent viral infection and spread.
Potential Applications of Lomtegovimab Biosimilar
Lomtegovimab Biosimilar is currently in preclinical development, with potential applications in the treatment and prevention of COVID-19. As a biosimilar to lomtegravir, it is expected to have similar efficacy and safety profiles, making it a promising candidate for use in patients with COVID-19. The antibody could also be used as a prophylactic treatment for individuals at high risk of exposure to the virus, such as healthcare workers.
Conclusion
In summary, Lomtegovimab Biosimilar is a recombinant humanized monoclonal antibody designed to target the RBD of the spike protein of SARS-CoV-2. Its high affinity binding to the RBD and ability to induce effector functions make it a promising candidate for the treatment and prevention of COVID-19. Further studies and clinical trials are needed to fully evaluate the potential of this antibody in combating the ongoing pandemic.
Reviews
There are no reviews yet.